ALKS Q4 2025 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$385M-10.6% YoY

Gross Profit

$333M86.5% margin

Operating Income

$58M15.1% margin

Net Income

$49M12.8% margin

EPS (Diluted)

$0.29

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

$170M

Free Cash Flow

$170M

Stock-Based Comp.

-$72M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$668M

Stockholders' Equity

$1.8B

Cash & Equivalents

$588M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$385M	$430M	-10.6%
Gross Profit	$333M	$368M	-9.6%
Operating Income	$58M	$163M	-64.3%
Net Income	$49M	$147M	-66.3%

Revenue Segments

Manufactured Product And Royalty

$229M37%

Vivitrol

$225M36%

Aristada And Aristada Initio

$171M27%